img

Global Hereditary Angioedema Drug Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Hereditary Angioedema Drug Market Insights, Forecast to 2034

In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adultsthe C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.
Global Hereditary Angioedema Drug market is expected to reach to US$ 772 million in 2024, with a positive growth of %, compared with US$ 743 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Hereditary Angioedema Drug industry is evaluated to reach US$ 1145.6 million in 2029. The CAGR will be 6.8% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Hereditary Angioedema Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Hereditary Angioedema Drug market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Segment by Type
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

Segment by Application


Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Hereditary Angioedema Drug plant distribution, commercial date of Hereditary Angioedema Drug, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Hereditary Angioedema Drug introduction, etc. Hereditary Angioedema Drug Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Hereditary Angioedema Drug
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Hereditary Angioedema Drug Product Introduction
1.2 Market by Type
1.2.1 Global Hereditary Angioedema Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 C1 Esterase Inhibitor
1.2.3 Kallikrein Inhibitor
1.2.4 Selective Bradykinin B2 Receptor Antagonist
1.3 Market by Application
1.3.1 Global Hereditary Angioedema Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Hereditary Angioedema Drug Sales Estimates and Forecasts 2018-2029
2.2 Global Hereditary Angioedema Drug Revenue by Region
2.2.1 Global Hereditary Angioedema Drug Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Hereditary Angioedema Drug Revenue by Region (2018-2024)
2.2.3 Global Hereditary Angioedema Drug Revenue by Region (2024-2029)
2.2.4 Global Hereditary Angioedema Drug Revenue Market Share by Region (2018-2029)
2.3 Global Hereditary Angioedema Drug Sales Estimates and Forecasts 2018-2029
2.4 Global Hereditary Angioedema Drug Sales by Region
2.4.1 Global Hereditary Angioedema Drug Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Hereditary Angioedema Drug Sales by Region (2018-2024)
2.4.3 Global Hereditary Angioedema Drug Sales by Region (2024-2029)
2.4.4 Global Hereditary Angioedema Drug Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Hereditary Angioedema Drug Sales by Manufacturers
3.1.1 Global Hereditary Angioedema Drug Sales by Manufacturers (2018-2024)
3.1.2 Global Hereditary Angioedema Drug Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Hereditary Angioedema Drug in 2022
3.2 Global Hereditary Angioedema Drug Revenue by Manufacturers
3.2.1 Global Hereditary Angioedema Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Hereditary Angioedema Drug Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Hereditary Angioedema Drug Revenue in 2022
3.3 Global Key Players of Hereditary Angioedema Drug, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Hereditary Angioedema Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Hereditary Angioedema Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Hereditary Angioedema Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Hereditary Angioedema Drug, Product Offered and Application
3.8 Global Key Manufacturers of Hereditary Angioedema Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Hereditary Angioedema Drug Sales by Type
4.1.1 Global Hereditary Angioedema Drug Historical Sales by Type (2018-2024)
4.1.2 Global Hereditary Angioedema Drug Forecasted Sales by Type (2024-2029)
4.1.3 Global Hereditary Angioedema Drug Sales Market Share by Type (2018-2029)
4.2 Global Hereditary Angioedema Drug Revenue by Type
4.2.1 Global Hereditary Angioedema Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Hereditary Angioedema Drug Forecasted Revenue by Type (2024-2029)
4.2.3 Global Hereditary Angioedema Drug Revenue Market Share by Type (2018-2029)
4.3 Global Hereditary Angioedema Drug Price by Type
4.3.1 Global Hereditary Angioedema Drug Price by Type (2018-2024)
4.3.2 Global Hereditary Angioedema Drug Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Hereditary Angioedema Drug Sales by Application
5.1.1 Global Hereditary Angioedema Drug Historical Sales by Application (2018-2024)
5.1.2 Global Hereditary Angioedema Drug Forecasted Sales by Application (2024-2029)
5.1.3 Global Hereditary Angioedema Drug Sales Market Share by Application (2018-2029)
5.2 Global Hereditary Angioedema Drug Revenue by Application
5.2.1 Global Hereditary Angioedema Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Hereditary Angioedema Drug Forecasted Revenue by Application (2024-2029)
5.2.3 Global Hereditary Angioedema Drug Revenue Market Share by Application (2018-2029)
5.3 Global Hereditary Angioedema Drug Price by Application
5.3.1 Global Hereditary Angioedema Drug Price by Application (2018-2024)
5.3.2 Global Hereditary Angioedema Drug Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Hereditary Angioedema Drug Market Size by Type
6.1.1 US & Canada Hereditary Angioedema Drug Sales by Type (2018-2029)
6.1.2 US & Canada Hereditary Angioedema Drug Revenue by Type (2018-2029)
6.2 US & Canada Hereditary Angioedema Drug Market Size by Application
6.2.1 US & Canada Hereditary Angioedema Drug Sales by Application (2018-2029)
6.2.2 US & Canada Hereditary Angioedema Drug Revenue by Application (2018-2029)
6.3 US & Canada Hereditary Angioedema Drug Market Size by Country
6.3.1 US & Canada Hereditary Angioedema Drug Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Hereditary Angioedema Drug Sales by Country (2018-2029)
6.3.3 US & Canada Hereditary Angioedema Drug Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Hereditary Angioedema Drug Market Size by Type
7.1.1 Europe Hereditary Angioedema Drug Sales by Type (2018-2029)
7.1.2 Europe Hereditary Angioedema Drug Revenue by Type (2018-2029)
7.2 Europe Hereditary Angioedema Drug Market Size by Application
7.2.1 Europe Hereditary Angioedema Drug Sales by Application (2018-2029)
7.2.2 Europe Hereditary Angioedema Drug Revenue by Application (2018-2029)
7.3 Europe Hereditary Angioedema Drug Market Size by Country
7.3.1 Europe Hereditary Angioedema Drug Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Hereditary Angioedema Drug Sales by Country (2018-2029)
7.3.3 Europe Hereditary Angioedema Drug Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Hereditary Angioedema Drug Market Size
8.1.1 China Hereditary Angioedema Drug Sales (2018-2029)
8.1.2 China Hereditary Angioedema Drug Revenue (2018-2029)
8.2 China Hereditary Angioedema Drug Market Size by Application
8.2.1 China Hereditary Angioedema Drug Sales by Application (2018-2029)
8.2.2 China Hereditary Angioedema Drug Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Hereditary Angioedema Drug Market Size by Type
9.1.1 Asia Hereditary Angioedema Drug Sales by Type (2018-2029)
9.1.2 Asia Hereditary Angioedema Drug Revenue by Type (2018-2029)
9.2 Asia Hereditary Angioedema Drug Market Size by Application
9.2.1 Asia Hereditary Angioedema Drug Sales by Application (2018-2029)
9.2.2 Asia Hereditary Angioedema Drug Revenue by Application (2018-2029)
9.3 Asia Hereditary Angioedema Drug Sales by Region
9.3.1 Asia Hereditary Angioedema Drug Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Hereditary Angioedema Drug Revenue by Region (2018-2029)
9.3.3 Asia Hereditary Angioedema Drug Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Hereditary Angioedema Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Hereditary Angioedema Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Pharming Group NV
11.1.1 Pharming Group NV Company Information
11.1.2 Pharming Group NV Overview
11.1.3 Pharming Group NV Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Pharming Group NV Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Pharming Group NV Recent Developments
11.2 Takeda
11.2.1 Takeda Company Information
11.2.2 Takeda Overview
11.2.3 Takeda Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Takeda Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Takeda Recent Developments
11.3 CSL Limited
11.3.1 CSL Limited Company Information
11.3.2 CSL Limited Overview
11.3.3 CSL Limited Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 CSL Limited Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 CSL Limited Recent Developments
11.4 IBio Inc.
11.4.1 IBio Inc. Company Information
11.4.2 IBio Inc. Overview
11.4.3 IBio Inc. Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 IBio Inc. Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 IBio Inc. Recent Developments
11.5 BioCryst Pharmaceuticals, Inc.
11.5.1 BioCryst Pharmaceuticals, Inc. Company Information
11.5.2 BioCryst Pharmaceuticals, Inc. Overview
11.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 BioCryst Pharmaceuticals, Inc. Recent Developments
11.6 Ionis Pharmaceuticals, Inc.
11.6.1 Ionis Pharmaceuticals, Inc. Company Information
11.6.2 Ionis Pharmaceuticals, Inc. Overview
11.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Ionis Pharmaceuticals, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Hereditary Angioedema Drug Industry Chain Analysis
12.2 Hereditary Angioedema Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hereditary Angioedema Drug Production Mode & Process
12.4 Hereditary Angioedema Drug Sales and Marketing
12.4.1 Hereditary Angioedema Drug Sales Channels
12.4.2 Hereditary Angioedema Drug Distributors
12.5 Hereditary Angioedema Drug Customers
13 Market Dynamics
13.1 Hereditary Angioedema Drug Industry Trends
13.2 Hereditary Angioedema Drug Market Drivers
13.3 Hereditary Angioedema Drug Market Challenges
13.4 Hereditary Angioedema Drug Market Restraints
14 Key Findings in The Global Hereditary Angioedema Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Hereditary Angioedema Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of C1 Esterase Inhibitor
Table 3. Major Manufacturers of Kallikrein Inhibitor
Table 4. Major Manufacturers of Selective Bradykinin B2 Receptor Antagonist
Table 5. Global Hereditary Angioedema Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Hereditary Angioedema Drug Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Hereditary Angioedema Drug Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Hereditary Angioedema Drug Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Hereditary Angioedema Drug Revenue Market Share by Region (2018-2024)
Table 10. Global Hereditary Angioedema Drug Revenue Market Share by Region (2024-2029)
Table 11. Global Hereditary Angioedema Drug Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Hereditary Angioedema Drug Sales by Region (2018-2024) & (K Units)
Table 13. Global Hereditary Angioedema Drug Sales by Region (2024-2029) & (K Units)
Table 14. Global Hereditary Angioedema Drug Sales Market Share by Region (2018-2024)
Table 15. Global Hereditary Angioedema Drug Sales Market Share by Region (2024-2029)
Table 16. Global Hereditary Angioedema Drug Sales by Manufacturers (2018-2024) & (K Units)
Table 17. Global Hereditary Angioedema Drug Sales Share by Manufacturers (2018-2024)
Table 18. Global Hereditary Angioedema Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Hereditary Angioedema Drug Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Hereditary Angioedema Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Hereditary Angioedema Drug Price by Manufacturers 2018-2024 (USD/Unit)
Table 22. Global Hereditary Angioedema Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Hereditary Angioedema Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hereditary Angioedema Drug as of 2022)
Table 24. Global Key Manufacturers of Hereditary Angioedema Drug, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Hereditary Angioedema Drug, Product Offered and Application
Table 26. Global Key Manufacturers of Hereditary Angioedema Drug, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Hereditary Angioedema Drug Sales by Type (2018-2024) & (K Units)
Table 29. Global Hereditary Angioedema Drug Sales by Type (2024-2029) & (K Units)
Table 30. Global Hereditary Angioedema Drug Sales Share by Type (2018-2024)
Table 31. Global Hereditary Angioedema Drug Sales Share by Type (2024-2029)
Table 32. Global Hereditary Angioedema Drug Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Hereditary Angioedema Drug Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Hereditary Angioedema Drug Revenue Share by Type (2018-2024)
Table 35. Global Hereditary Angioedema Drug Revenue Share by Type (2024-2029)
Table 36. Hereditary Angioedema Drug Price by Type (2018-2024) & (USD/Unit)
Table 37. Global Hereditary Angioedema Drug Price Forecast by Type (2024-2029) & (USD/Unit)
Table 38. Global Hereditary Angioedema Drug Sales by Application (2018-2024) & (K Units)
Table 39. Global Hereditary Angioedema Drug Sales by Application (2024-2029) & (K Units)
Table 40. Global Hereditary Angioedema Drug Sales Share by Application (2018-2024)
Table 41. Global Hereditary Angioedema Drug Sales Share by Application (2024-2029)
Table 42. Global Hereditary Angioedema Drug Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Hereditary Angioedema Drug Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Hereditary Angioedema Drug Revenue Share by Application (2018-2024)
Table 45. Global Hereditary Angioedema Drug Revenue Share by Application (2024-2029)
Table 46. Hereditary Angioedema Drug Price by Application (2018-2024) & (USD/Unit)
Table 47. Global Hereditary Angioedema Drug Price Forecast by Application (2024-2029) & (USD/Unit)
Table 48. US & Canada Hereditary Angioedema Drug Sales by Type (2018-2024) & (K Units)
Table 49. US & Canada Hereditary Angioedema Drug Sales by Type (2024-2029) & (K Units)
Table 50. US & Canada Hereditary Angioedema Drug Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Hereditary Angioedema Drug Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Hereditary Angioedema Drug Sales by Application (2018-2024) & (K Units)
Table 53. US & Canada Hereditary Angioedema Drug Sales by Application (2024-2029) & (K Units)
Table 54. US & Canada Hereditary Angioedema Drug Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Hereditary Angioedema Drug Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Hereditary Angioedema Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Hereditary Angioedema Drug Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Hereditary Angioedema Drug Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Hereditary Angioedema Drug Sales by Country (2018-2024) & (K Units)
Table 60. US & Canada Hereditary Angioedema Drug Sales by Country (2024-2029) & (K Units)
Table 61. Europe Hereditary Angioedema Drug Sales by Type (2018-2024) & (K Units)
Table 62. Europe Hereditary Angioedema Drug Sales by Type (2024-2029) & (K Units)
Table 63. Europe Hereditary Angioedema Drug Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Hereditary Angioedema Drug Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Hereditary Angioedema Drug Sales by Application (2018-2024) & (K Units)
Table 66. Europe Hereditary Angioedema Drug Sales by Application (2024-2029) & (K Units)
Table 67. Europe Hereditary Angioedema Drug Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Hereditary Angioedema Drug Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Hereditary Angioedema Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Hereditary Angioedema Drug Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Hereditary Angioedema Drug Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Hereditary Angioedema Drug Sales by Country (2018-2024) & (K Units)
Table 73. Europe Hereditary Angioedema Drug Sales by Country (2024-2029) & (K Units)
Table 74. China Hereditary Angioedema Drug Sales by Type (2018-2024) & (K Units)
Table 75. China Hereditary Angioedema Drug Sales by Type (2024-2029) & (K Units)
Table 76. China Hereditary Angioedema Drug Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Hereditary Angioedema Drug Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Hereditary Angioedema Drug Sales by Application (2018-2024) & (K Units)
Table 79. China Hereditary Angioedema Drug Sales by Application (2024-2029) & (K Units)
Table 80. China Hereditary Angioedema Drug Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Hereditary Angioedema Drug Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Hereditary Angioedema Drug Sales by Type (2018-2024) & (K Units)
Table 83. Asia Hereditary Angioedema Drug Sales by Type (2024-2029) & (K Units)
Table 84. Asia Hereditary Angioedema Drug Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Hereditary Angioedema Drug Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Hereditary Angioedema Drug Sales by Application (2018-2024) & (K Units)
Table 87. Asia Hereditary Angioedema Drug Sales by Application (2024-2029) & (K Units)
Table 88. Asia Hereditary Angioedema Drug Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Hereditary Angioedema Drug Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Hereditary Angioedema Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Hereditary Angioedema Drug Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Hereditary Angioedema Drug Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Hereditary Angioedema Drug Sales by Region (2018-2024) & (K Units)
Table 94. Asia Hereditary Angioedema Drug Sales by Region (2024-2029) & (K Units)
Table 95. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Type (2018-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Type (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Application (2018-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Application (2024-2029) & (K Units)
Table 101. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Country (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales by Country (2024-2029) & (K Units)
Table 108. Pharming Group NV Company Information
Table 109. Pharming Group NV Description and Major Businesses
Table 110. Pharming Group NV Hereditary Angioedema Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 111. Pharming Group NV Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Pharming Group NV Recent Developments
Table 113. Takeda Company Information
Table 114. Takeda Description and Major Businesses
Table 115. Takeda Hereditary Angioedema Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 116. Takeda Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Takeda Recent Developments
Table 118. CSL Limited Company Information
Table 119. CSL Limited Description and Major Businesses
Table 120. CSL Limited Hereditary Angioedema Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 121. CSL Limited Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. CSL Limited Recent Developments
Table 123. IBio Inc. Company Information
Table 124. IBio Inc. Description and Major Businesses
Table 125. IBio Inc. Hereditary Angioedema Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 126. IBio Inc. Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. IBio Inc. Recent Developments
Table 128. BioCryst Pharmaceuticals, Inc. Company Information
Table 129. BioCryst Pharmaceuticals, Inc. Description and Major Businesses
Table 130. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 131. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. BioCryst Pharmaceuticals, Inc. Recent Developments
Table 133. Ionis Pharmaceuticals, Inc. Company Information
Table 134. Ionis Pharmaceuticals, Inc. Description and Major Businesses
Table 135. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 136. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Ionis Pharmaceuticals, Inc. Recent Developments
Table 138. Key Raw Materials Lists
Table 139. Raw Materials Key Suppliers Lists
Table 140. Hereditary Angioedema Drug Distributors List
Table 141. Hereditary Angioedema Drug Customers List
Table 142. Hereditary Angioedema Drug Market Trends
Table 143. Hereditary Angioedema Drug Market Drivers
Table 144. Hereditary Angioedema Drug Market Challenges
Table 145. Hereditary Angioedema Drug Market Restraints
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Hereditary Angioedema Drug Product Picture
Figure 2. Global Hereditary Angioedema Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Hereditary Angioedema Drug Market Share by Type in 2022 & 2029
Figure 4. C1 Esterase Inhibitor Product Picture
Figure 5. Kallikrein Inhibitor Product Picture
Figure 6. Selective Bradykinin B2 Receptor Antagonist Product Picture
Figure 7. Global Hereditary Angioedema Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Hereditary Angioedema Drug Market Share by Application in 2022 & 2029
Figure 9. Retail Pharmacies
Figure 10. Hospital Pharmacies
Figure 11. Online Pharmacies
Figure 12. Hereditary Angioedema Drug Report Years Considered
Figure 13. Global Hereditary Angioedema Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Hereditary Angioedema Drug Revenue 2018-2029 (US$ Million)
Figure 15. Global Hereditary Angioedema Drug Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Hereditary Angioedema Drug Revenue Market Share by Region (2018-2029)
Figure 17. Global Hereditary Angioedema Drug Sales 2018-2029 ((K Units)
Figure 18. Global Hereditary Angioedema Drug Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Hereditary Angioedema Drug Sales YoY (2018-2029) & (K Units)
Figure 20. US & Canada Hereditary Angioedema Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Hereditary Angioedema Drug Sales YoY (2018-2029) & (K Units)
Figure 22. Europe Hereditary Angioedema Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Hereditary Angioedema Drug Sales YoY (2018-2029) & (K Units)
Figure 24. China Hereditary Angioedema Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Hereditary Angioedema Drug Sales YoY (2018-2029) & (K Units)
Figure 26. Asia (excluding China) Hereditary Angioedema Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales YoY (2018-2029) & (K Units)
Figure 28. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 29. The Hereditary Angioedema Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Hereditary Angioedema Drug in the World: Market Share by Hereditary Angioedema Drug Revenue in 2022
Figure 31. Global Hereditary Angioedema Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Hereditary Angioedema Drug Sales Market Share by Type (2018-2029)
Figure 33. Global Hereditary Angioedema Drug Revenue Market Share by Type (2018-2029)
Figure 34. Global Hereditary Angioedema Drug Sales Market Share by Application (2018-2029)
Figure 35. Global Hereditary Angioedema Drug Revenue Market Share by Application (2018-2029)
Figure 36. US & Canada Hereditary Angioedema Drug Sales Market Share by Type (2018-2029)
Figure 37. US & Canada Hereditary Angioedema Drug Revenue Market Share by Type (2018-2029)
Figure 38. US & Canada Hereditary Angioedema Drug Sales Market Share by Application (2018-2029)
Figure 39. US & Canada Hereditary Angioedema Drug Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Hereditary Angioedema Drug Revenue Share by Country (2018-2029)
Figure 41. US & Canada Hereditary Angioedema Drug Sales Share by Country (2018-2029)
Figure 42. U.S. Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 43. Canada Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 44. Europe Hereditary Angioedema Drug Sales Market Share by Type (2018-2029)
Figure 45. Europe Hereditary Angioedema Drug Revenue Market Share by Type (2018-2029)
Figure 46. Europe Hereditary Angioedema Drug Sales Market Share by Application (2018-2029)
Figure 47. Europe Hereditary Angioedema Drug Revenue Market Share by Application (2018-2029)
Figure 48. Europe Hereditary Angioedema Drug Revenue Share by Country (2018-2029)
Figure 49. Europe Hereditary Angioedema Drug Sales Share by Country (2018-2029)
Figure 50. Germany Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 51. France Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 52. U.K. Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 53. Italy Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 54. Russia Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 55. China Hereditary Angioedema Drug Sales Market Share by Type (2018-2029)
Figure 56. China Hereditary Angioedema Drug Revenue Market Share by Type (2018-2029)
Figure 57. China Hereditary Angioedema Drug Sales Market Share by Application (2018-2029)
Figure 58. China Hereditary Angioedema Drug Revenue Market Share by Application (2018-2029)
Figure 59. Asia Hereditary Angioedema Drug Sales Market Share by Type (2018-2029)
Figure 60. Asia Hereditary Angioedema Drug Revenue Market Share by Type (2018-2029)
Figure 61. Asia Hereditary Angioedema Drug Sales Market Share by Application (2018-2029)
Figure 62. Asia Hereditary Angioedema Drug Revenue Market Share by Application (2018-2029)
Figure 63. Asia Hereditary Angioedema Drug Revenue Share by Region (2018-2029)
Figure 64. Asia Hereditary Angioedema Drug Sales Share by Region (2018-2029)
Figure 65. Japan Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 66. South Korea Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 67. China Taiwan Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 68. Southeast Asia Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 69. India Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Hereditary Angioedema Drug Revenue Share by Country (2018-2029)
Figure 75. Middle East, Africa and Latin America Hereditary Angioedema Drug Sales Share by Country (2018-2029)
Figure 76. Brazil Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 77. Mexico Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 78. Turkey Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 79. Israel Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 80. GCC Countries Hereditary Angioedema Drug Revenue (2018-2029) & (US$ Million)
Figure 81. Hereditary Angioedema Drug Value Chain
Figure 82. Hereditary Angioedema Drug Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries